See more : Williams Rowland Acquisition Corp. (WRAC) Income Statement Analysis – Financial Results
Complete financial analysis of Health Sciences Acquisitions Corporation 2 (HSAQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Health Sciences Acquisitions Corporation 2, a leading company in the Shell Companies industry within the Financial Services sector.
- Young Optics Inc. (3504.TW) Income Statement Analysis – Financial Results
- Veritiv Corporation (VRTV) Income Statement Analysis – Financial Results
- Rap Media Limited (RAP.BO) Income Statement Analysis – Financial Results
- Raven Gold Corp. (RVNG) Income Statement Analysis – Financial Results
- Viracta Therapeutics, Inc. (VIRX) Income Statement Analysis – Financial Results
Health Sciences Acquisitions Corporation 2 (HSAQ)
Industry: Shell Companies
Sector: Financial Services
About Health Sciences Acquisitions Corporation 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.96M | 274.76K | 129.99K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.96M | 274.76K | 129.99K |
| Other Expenses | 0.00 | 0.00 | 50.00K |
| Operating Expenses | 2.96M | 274.76K | 179.99K |
| Cost & Expenses | 2.96M | 274.76K | 179.99K |
| Interest Income | 345.14K | 16.00K | 0.00 |
| Interest Expense | -345.14K | -16.00K | 0.00 |
| Depreciation & Amortization | 345.14K | 16.00K | 206.30K |
| EBITDA | -2.74M | -378.75K | -173.54K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.08M | -394.76K | -173.54K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 345.14K | 16.00K | 0.00 |
| Income Before Tax | -2.74M | -378.75K | -173.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -345.14K | -16.00K | 0.00 |
| Net Income | -2.39M | -362.75K | -173.54K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.15 | -0.02 | -0.01 |
| EPS Diluted | -0.15 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 16.43M | 20.27M | 20.27M |
| Weighted Avg Shares Out (Dil) | 16.43M | 20.27M | 20.27M |
Source: https://incomestatements.info
Category: Stock Reports